AMPLIFY-EXT trial of Eliquis(Apixaban) shows positive results

AMPLIFY -EXT trial of Eliquis(Apixaban)shows positive results in phase3 trial. This trial evaluated clinical and demographic predictors of all cause hospitalization in patients suffering from VTE,which include DVT and PE.DVT stands for Deep vein thrombosis and PE stands for Pulmonary embolism .
  This Phase 3 trial included randomized ,double blinded,placebo controlled , extended treatment (AMPLIFY-EXT) for 12 months .
 Out of 2486 total patients,138 patients were hospitalized during this AMPLIFY-EXT trial at least once.
      With this 12 month extended treatment of VTE ,and its positive results provides additional support for extended anti coagulation support with Eliquis(Apixaban) in VTE patients .
BMS and Pfizer are the developers of this Eliquis drug. 

Eliquis sNDA has been approved by FDA for treatment in DVT and PE

Eliquis  Supplemental New drug application,sNDA has been approved by the US FDA for treatment of DVT and PE(Blood clots ) and for reduction of risk of Recurrent DVT and PE after initial treatment(therapy)
DVT is blood clot in vein,generally in lower leg or thigh or pelvis which causes partial or complete halt of blood flow in these regions.PE is blood clot in one or more LUNG vessels ,blocking them.DVT progresses to PE if left untreated. DVT and PE together are called VTE.
Eliquis ,(Apixaban) is an oral selective Factor Xa inhibitor,an important blood clotting protein.By inhibiting this it decreases blood clot formation.